- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02668068
A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells
A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis
Pneumoconiosis is a kind of lung disease due to inhalation of dust such as silica(common named Silicosis), coal and rock dust, characterized by inflammation, coughing, and fibrosis. Currently there is no effective drug treatment. The whole-lung lavage(WLL) can effectively clear the protein-like substances and inhaled dust deposited in the alveoli and bronchioles, as well as the pulmonary alveolar macrophage(PAM) and the resulting induced inflammation, fibrosis induced factor, serve to improve respiratory function, relieve symptoms of efficacy, but can't slow down or reverse the progression of pulmonary fibrosis.
By taking large volume whole-lung lavage (WLL) as a conventional therapy, this study intends to observe and evaluate the safety and efficiency of combined large volume WLL with mesenchymal stem cell (MSC) transplantation for treatment of Pneumoconiosis. Moreover, the immune regulation effect between large volume WLL and combined large volume WLL with MSC transplantation will also be preliminarily investigated and discussed.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400038
- First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Nanjing Chest Hosptial
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18-70 years old.
- Subjects had exposed to dusts with a long history.
- Subjects with a clear clinical diagnosis to be silicotics or coal miners' pneumoconiosis patients.
- Subjects with each detected index of pulmonary function test including FVC, FEV1 or MVV had exceeded 70% of the predicated value.
- Subjects signed informed consent.
Exclusion Criteria:
- Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures.
- Subjects with syphilis or HIV positive antibody.
- Subjects with infection aggravated within the past month.
- Subjects suffering from any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, severe pneumonia, acute exacerbation of chronic bronchitis, AECOPD, severe and / or extremely severe COPD, etc..
- Subjects suffering from other serious diseases, such as myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis.
- Subjects suffering from other life-threatening diseases with an estimated life-span less than 2 years.
- Subjects with leukopenia (WBC less than 4x109 / L) or agranulocytosis (WBC less than 1.5x109 / L or neutrophils less than 0.5x109 / L) caused by any reason.
- Subjects with severe renal impairment, serum creatinine> 1.5 times the upper limit of normal.
- Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times the upper limit of normal
- Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
- Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
- Subjects with a history of alcohol or illicit drug abuse.
- Subjects accepted by any other clinical trials within 3 months before the enrollment.
- Subjects with poor compliance, difficult to complete the study.
- Any other conditions that might increase the risk of subjects or interfere with the clinical trial.
- Subjects accepted large volume whole-lung lavage treatment previously.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Group
Large volume whole-lung lavage (WLL) only
|
Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
|
Experimental: Experimental Group
Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
|
Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)
Time Frame: 6 months
|
Clinical adverse events evaluated as definitely/ probably/possibly concerned with large volume lung lavage and / or mesenchymal stem cell therapy in this trial, and abnormal results of laboratory tests or other special examinations will be observed and recorded in detail.
|
6 months
|
Imaging indicator: Quantitative analysis of CT density histograms
Time Frame: 6 months after surgery
|
6 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Indicator 1: change in blood gas analysis
Time Frame: 6 months
|
Including PH, PaCO2,PaO2, HCO3
|
6 months
|
Clinical Indicator 2: change in MRC chronic dyspnea scale
Time Frame: 6 months
|
6 months
|
|
Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale
Time Frame: 6 months
|
6 months
|
|
Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)
Time Frame: 6 months
|
6 months
|
|
Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)
Time Frame: 6 months
|
6 months
|
|
Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF
Time Frame: 6 months
|
6 months
|
|
Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF
Time Frame: 6 months
|
6 months
|
|
Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9
Time Frame: 6 months
|
6 months
|
|
Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9
Time Frame: 6 months
|
6 months
|
|
self-evaluation
Time Frame: 6 months
|
Self-evaluation will be also classified into four levels: effective, improved, stable and invalid
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Wei Xiong, M.D, First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)
- Study Director: Xiaotian Dai,, M.M, First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)
- Study Director: Yingming Zhang, M.M, Nanjing Chest Hospital
- Study Director: Shencun Fang, M.M, Nanjing Chest Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAS-XDA-SH/NCH/IGDB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumoconiosis
-
Pulmonary Research of Abingdon, LLCGenentech, Inc.CompletedCoal Workers' Pneumoconiosis (Complicated)United States
-
Holdsworth House Medical PracticeBoehringer IngelheimRecruitingSilicosis | Pneumoconiosis Coal | AsbestosisAustralia
-
Henan University of Traditional Chinese MedicineUnknown
-
University of OklahomaCompletedSilicosis | Pneumoconiosis; SilicaUnited States
-
Peking University Third HospitalRecruiting
-
Peking University Third HospitalCompleted
-
Chinese University of Hong KongCompletedPneumoconiosisHong Kong
-
The University of QueenslandThe Alfred; Royal Prince Alfred Hospital, Sydney, Australia; The Prince Charles... and other collaboratorsRecruiting
-
The University of QueenslandNot yet recruiting
Clinical Trials on large volume whole-lung lavage (WLL)
-
Shanghai Pulmonary Hospital, Shanghai, ChinaUnknownPulmonary Alveolar ProteinosisChina
-
The University of QueenslandNot yet recruiting